Ab­b­Vie, Scripps ex­pand part­ner­ship, for­ti­fy fo­cus on can­cer drugs

Scripps and Ab­b­Vie go way back. Re­search con­duct­ed in the lab of Scripps sci­en­tist Richard Lern­er led to the dis­cov­ery of Hu­mi­ra. The an­ti­body, ap­proved by the FDA in 2002 and sold by Ab­b­Vie, went on to be­come the world’s best­selling treat­ment. In 2018, the drug­mak­er and the non-prof­it or­ga­ni­za­tion signed a pact fo­cused on de­vel­op­ing can­cer treat­ments — and now, the scope of that part­ner­ship has broad­ened to en­com­pass a range of dis­eases, in­clud­ing im­muno­log­i­cal and neu­ro­log­i­cal con­di­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER